Children's Hospital of Philadelphia

Poker Player Dan Shak to Participate in 2024 World Series of Poker

Retrieved on:

수요일, 5월 8, 2024

Table, WSOP, Hospital, PokerGO, No Limit, Global Poker Index, Partnership, 135th, Children's Hospital of Philadelphia, U.S. Poker Open

LAS VEGAS, May 8, 2024 /PRNewswire-PRWeb/ -- Semi-pro poker player Dan Shak is set to compete at the 2024 World Series of Poker, beginning on May 28 in Las Vegas. Shak is seeking his first WSOP bracelet after a series of recent near victories in prior WSOP events.

Key Points:

LAS VEGAS, May 8, 2024 /PRNewswire-PRWeb/ -- Semi-pro poker player Dan Shak is set to compete at the 2024 World Series of Poker, beginning on May 28 in Las Vegas.
Shak is seeking his first WSOP bracelet after a series of recent near victories in prior WSOP events.
Shak's strong start to 2024 adds to numerous achievements on the poker circuit, including multiple appearances at the final tables of high stakes events such as the PokerGO Cup, Poker Masters, and U.S.
Shak, co-founder of the "All-In" for Kids Poker Tournament in partnership with The Children's Hospital of Philadelphia and the WPT Foundation, is currently ranked 135th in the Global Poker Index and 114th in the 2024 Player of the Year standings.

CHOP and NJ HTS Launch New Website Dedicated to Promoting Traffic Safety

Retrieved on:

화요일, 5월 7, 2024

Rail transport by country, Information technology, Transport, Hospital, Safety, CHOP, Research, Collection, Doctor of Philosophy, CIRP, HTS, Department of motor vehicles, Fatality, Crash, Death, Children's Hospital of Philadelphia, Pedestrian

PHILADELPHIA, May 7, 2024 /PRNewswire/ -- Children's Hospital of Philadelphia (CHOP)'s New Jersey Safety and Health Outcomes (NJ-SHO) Center for Integrated Data and the New Jersey Division of Highway Traffic Safety (HTS) are pleased to announce the launch of njsho.chop.edu, a website that features an interactive data dashboard that enables users to visualize, monitor, and track important traffic safety measures across communities and over time.

Key Points:

The NJ-SHO Center for Integrated Data team is reimagining how data are collected, integrated, analyzed, and shared to support safe transport in New Jersey.
The data dashboard offers access to previously unavailable data to guide and evaluate local and statewide solutions for reducing the burden of injury and deaths.
The website also shares evidence-based injury prevention, transportation equity, and traffic safety resources to help drive positive change throughout the state.
"We hope that regional, local, and community partners will use our dashboard to implement safety efforts that ultimately move the needle on reducing crashes."

CHOP Study Finds Healthcare Providers Play Crucial Role in Guiding Autistic Adolescents and Their Families into Adulthood

Retrieved on:

월요일, 4월 29, 2024

Online, Bangladesh Technical Education Board, Spectrum, Learning, Hospital, CHOP, Research, DSM-IV codes, Health care, Doctor of Philosophy, Transport, CIRP, Licensure, Child, Caregiver, Children's Hospital of Philadelphia, Quality of life, Journal, Nursing

The study also highlighted the crucial role of healthcare providers in fostering collaborative decision-making around key milestones for adulthood, along with support strategies to help families assess driving readiness.

Key Points:

The study also highlighted the crucial role of healthcare providers in fostering collaborative decision-making around key milestones for adulthood, along with support strategies to help families assess driving readiness.
Healthcare providers are eager to improve quality of life for autistic adolescents by acting as facilitators during this transitional time.
Providers recognized that working towards independence can offer significant benefits for autistic youths and their families.
Preparing to "Live a Life of Possibilities": Experiences of Healthcare Providers Readying Autistic Adolescents and Their Families for Independent Driving.

CHOP Researchers Discover Underlying Biology Behind Fontan-Associated Liver Disease

Retrieved on:

수요일, 4월 24, 2024

PHILADELPHIA, April 24, 2024 /PRNewswire/ -- As patients with congenital heart diseases live longer, researchers are attempting to understand some of the other complications they may face as they age. In a new study, a team from Children's Hospital of Philadelphia (CHOP) used state-of-the-art technologies to understand the underlying biology of Fontan-associated liver disease (FALD).

Key Points:

In a new study, a team from Children's Hospital of Philadelphia (CHOP) used state-of-the-art technologies to understand the underlying biology of Fontan-associated liver disease (FALD).
The Fontan operation is the current standard of care for single-ventricle congenital heart disease.
As more patients undergo the Fontan surgery for single-ventricle congenital heart disease, FALD has become a more recognized problem.
Little information exists on FALD, yet it is distinct from other forms of liver disease, which is why researchers at CHOP wanted to understand the basic biology that could lead to better treatment options and improve these patients' quality of life.

Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors

Retrieved on:

화요일, 4월 23, 2024

This approval makes Lutathera the first therapy specifically reviewed and approved for use in pediatric patients with GEP-NETs.

Key Points:

This approval makes Lutathera the first therapy specifically reviewed and approved for use in pediatric patients with GEP-NETs.
"Lutathera is now the very first therapy approved specifically for children with GEP-NETs, offering new hope to young patients living with this rare cancer," said Tina Deignan, Therapeutic Area Head, Oncology US.
NETs are a type of cancer that originates in neuroendocrine cells throughout the body and are commonly considered slow-growing malignancies1.
In addition, the estimated radiation absorbed dose in pediatric patients was within established organ thresholds for external beam radiation and comparable to that in adults for the approved dose.

In Celebration of National Volunteer Month, Children's Hospital of Philadelphia and The Wawa Foundation Announce Inaugural Helping Hands Community Care Challenge

Retrieved on:

화요일, 4월 23, 2024

PHILADELPHIA, April 23, 2024 /PRNewswire/ -- To celebrate April as National Volunteer Month, Children's Hospital of Philadelphia (CHOP) and The Wawa Foundation, commemorating its 10th anniversary this year, have come together to announce the inaugural Helping Hands Community Care Challenge taking place on Friday, September 13. The day-long event will bring together hundreds of representatives from local companies who will participate in various volunteer programs benefiting patients and families at CHOP.

Key Points:

Additionally, the well-known and beloved Wawa Coffee and Care Cart will be on-site serving attendees, sharing a marquee example of a volunteer activity at CHOP.
Funds raised through Helping Hands support Wawa Volunteer Services at CHOP, empowering the expansion and elevation of the volunteer program, engaging more community members and creating a ripple effect of kindness.
"We are thrilled to partner with CHOP to present the Helping Hands Community Care Challenge," said Maria Kalogredis, Chair of The Wawa Foundation.
To learn more about this inaugural event and how it will impact the community, go to helpinghands.chop.edu .

HealthQuest Capital Welcomes Ashley McEvoy to its Advisory Board

Retrieved on:

화요일, 4월 9, 2024

Worldwide, Growth, CHOP, IAB, Executive, SAN, McEvoy, Hospital, Ecosystem, Johnson & Johnson, Procter & Gamble, Children's Hospital of Philadelphia, Medtech, Pharmaceutical industry

SAN FRANCISCO, April 9, 2024 /PRNewswire/ -- HealthQuest Capital, a private asset firm that provides capital to transformative healthcare companies, today announced the addition of Ashley McEvoy to its Industry Advisory Board (IAB). McEvoy brings over 20 years of experience from Johnson & Johnson. This appointment will enhance HealthQuest Capital as a value-add investor for its ecosystem of portfolio companies by adding another complementary industry leader to drive progress within the healthcare space.

Key Points:

SAN FRANCISCO, April 9, 2024 /PRNewswire/ -- HealthQuest Capital , a private asset firm that provides capital to transformative healthcare companies, today announced the addition of Ashley McEvoy to its Industry Advisory Board (IAB).
This appointment will enhance HealthQuest Capital as a value-add investor for its ecosystem of portfolio companies by adding another complementary industry leader to drive progress within the healthcare space.
Ashley McEvoy is the former Executive Vice President and Worldwide Chairman of Johnson & Johnson's MedTech division, Ashley oversaw a vast organization with 60,000 global employees and revenue exceeding $30 billion.
"The addition of Ashley McEvoy strengthens our ability to identify and support innovative healthcare companies.

Mastery Schools, Children's Hospital of Philadelphia Announce Innovative Healthcare High School to Address Local Healthcare Workforce Shortages with Support from Bloomberg Philanthropies

Retrieved on:

금요일, 4월 5, 2024

PHILADELPHIA, April 5, 2024 /PRNewswire/ -- Children's Hospital of Philadelphia (CHOP) and Mastery Schools announced today an unprecedented partnership to design a high school that will help prepare students for well-paying careers in healthcare and address local education and healthcare talent needs. Through this initiative from Bloomberg Philanthropies, Mastery Hardy Williams High School will be revamped to fully integrate healthcare career knowledge and job-training with a high-quality, well-rounded high school experience for students in Philadelphia, graduating students directly into high-demand healthcare jobs at CHOP with family-sustaining wages.

Key Points:

Through this initiative from Bloomberg Philanthropies , Mastery Hardy Williams High School will be revamped to fully integrate healthcare career knowledge and job-training with a high-quality, well-rounded high school experience for students in Philadelphia, graduating students directly into high-demand healthcare jobs at CHOP with family-sustaining wages.
"By combining classroom learning with hands-on experience, these specialized health-care high schools will prepare students for careers with opportunities for growth and advancement.
Despite inflation, the labor market remains incredibly competitive, with shortages in every area from direct patient care to healthcare operations to administration.
Bloomberg Philanthropies' investment will support school start-up costs including personnel needs, classroom and lab renovations, and other work-based learning requirements.

Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy

Retrieved on:

수요일, 3월 20, 2024

TOKYO, LONDON and BOSTON, March 20, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced the details of its U.S. commercial launch of Lenmeldy™ (atidarsagene autotemcel), formerly known as OTL-200, the first FDA-approved therapy for the treatment of children with pre-symptomatic late infantile (PSLI), pre-symptomatic early juvenile, (PSEJ), or early symptomatic early juvenile (ESEJ)—collectively referred to as early-onset—metachromatic leukodystrophy (MLD).

Key Points:

Prior to Lenmeldy, there were no treatment options in the U.S. for early-onset MLD beyond supportive and end-of-life care.
This approach has the potential to restore enzymatic function to stop or slow disease progression with a single treatment.
Utilizing results from such studies, a multi-stakeholder working group is finalizing a nomination to add MLD to the U.S.
Based on current timelines and assumptions, Orchard Therapeutics expects the nomination will be submitted in mid-year 2024.

Children's Hospital of Philadelphia's Richard D. Wood Jr. Center for Fetal Diagnosis and Treatment Earns Two Press Ganey Awards

Retrieved on:

목요일, 3월 28, 2024

Surgeon, SDU, CHOP, Press Ganey Associates, Patient, Periodic function, Pinnacle, MD, Birth, Senior counsel, Hospital, Heart, Excellence, CFDT, Test management, Children's Hospital of Philadelphia, Parent, Nursing

PHILADELPHIA, March 28, 2024 /PRNewswire/ -- The Richard D. Wood Jr. Center for Fetal Diagnosis and Treatment (CFDT) at Children's Hospital of Philadelphia (CHOP) has once again received prestigious recognition from Press Ganey, a healthcare company that evaluates patient satisfaction.

Key Points:

As in 2022, 2021 and 2020, the CFDT won the 2023 Pinnacle of Excellence Award®, a preeminent, competitive achievement for leading healthcare organizations.
Presented annually, the award applauds hospitals and health systems that consistently sustain performance year-over-year.
"This award underscores the team's dedication to keeping our patients and families at the forefront of every decision and treatment option."
The SDU is the world's first birth facility in a pediatric hospital specifically designed for healthy mothers carrying babies with known birth defects.